Sanofi (SNY) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, everyone. This is Thomas Grusazen from the Zenobia IRR team. Welcome to the Q1 2025 conference call for investors and analysts. As usual, you can find the slides on zenobia.com. Please turn to slide number three, please. Here we have the usual forward-looking statements. We'd like to remind you that information presented in this call contains forward-looking statements which are subject to substantial risk and uncertainties that may cause active results to deeper material. We encourage you to read the disclaimer in our slide presentation. In addition, we refer to our new Form 20F on file with the U.S. Agency in our Friends Registration Document, a description of these risk factors. As last quarter, financials reported are under the new reporting scope that excludes the appellate consumer health business. As usual, we will be making comments on our performance using constant exchange rates and other non-IFRS measures. Numbers used are millions of euros, and for Q1 2025, one is stated otherwise. Now please turn to slide number four. First, we have a presentation, then we'll take your questions. We have kept the presentation as shown as in the past, and other companies report today, and we aim at keeping the call to maximum one hour. With Q&A, we have Brian, Olivier, Thomas to cover our global businesses, as well as Roy, our general counsel, and Brendan, head of manufacturing, and Tobias. With the Q&A, you have two options in Zoom. Raise your hand or submit your question using the Q&A function. With this, I'll hand you over to Paul. Well, thank you, Thomas. Nicely done. And hello, everyone on the call. We had a strong start to 2025 with a 9.7% sales growth in the first quarter. Our strategic focus on innovation continues to deliver, driven by pharma launches, D-P...